Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
41 hedge funds and large institutions have $18.4M invested in Clearside Biomedical in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 10 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
0.03% less ownership
Funds ownership: 1.75% → 1.72% (-0.03%)
9% less funds holding
Funds holding: 45 → 41 (-4)
17% less capital invested
Capital invested by funds: $22.2M → $18.4M (-$3.71M)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.06M |
| 2 |
CG
Carmignac Gestion
Paris,
France
|
+$867K |
| 3 |
Two Sigma Advisers
New York
|
+$178K |
| 4 |
Two Sigma Investments
New York
|
+$151K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$121K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$978K |
| 2 |
Renaissance Technologies
New York
|
-$487K |
| 3 |
Millennium Management
New York
|
-$272K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$229K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$134K |
CLSD Hedge Fund Activity: Q3 2020 in Review
41 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q3 2020, worth a combined $18.4M — down 17% from $22.2M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CLSD and 6 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 11 added.
The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $1.06M. The largest seller was Group One Trading, exiting entirely with an estimated $978K sold.
- 41 institutional investors held Clearside Biomedical (CLSD) as of Q3 2020, down from 45 in Q2 2020.
- Funds reported $18.4M of Clearside Biomedical stock for Q3 2020, down 17% quarter-over-quarter.
- 6 funds opened new Clearside Biomedical positions in Q3 2020 and 10 closed out, a net change of -4 holders.
- The largest Clearside Biomedical buyer in Q3 2020 was Acuta Capital Partners, an estimated $1.06M added.
- The largest Clearside Biomedical seller in Q3 2020 was Group One Trading, an estimated $978K sold.
Based on aggregated 13F filings for Q3 2020.